Antithrombotic drugs: Insights from cardiology

Cerebrovascular Diseases

Volumn 8, Issue SUPPL. 5, 1998, Pages 19-27

  Meyer, Beat J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acute coronary syndromes; Antiplatelet drugs; Aspirin; Coronary artery disease; Platelet glycoprotein IIb IIIa receptor inhibitors; Thienopyridines

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; THROMBIN; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN;

BLEEDING; CARDIOLOGY; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

CARDIOLOGY; CORONARY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY;

EID: 0031753075     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047514     Document Type: Conference Paper

References (47)

1. Bresnahan DR, Davis JL, Holmes DR Jr, Smith HC: Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus: Role of unstable angina. J Am Coll Cardiol 1985;6:285-289.
2. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME: Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: Natural history and the effect of thrombolysis. Circulation 1998;97:26-33.
3. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995;92:657-671.
4. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA: Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.
5. Merlini PA, Pauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD: Persistent activation of coagulation mechanism in unstable angina and myocardiol infarction. Circulation 1994;90:61-68.
6. Meyer BJ, Suhijar D, Delacrétaz E, Haeberli A, Beer JH: Failure of heparin and aspirin to consistently suppress local procoagulant activity during PTCA in patients with unstable angina (abstract). Circulation 1996;94(suppl):I-431.
7. Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Madimon L: Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: Comparison with heparin and aspirin. Circulation 1998;97:681-685.
8. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
9. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL: Platelets and shear stress. Blood 1996;88:1525-1541.
10. Rupprecht HJ, Daruis H, Borkowsky U, Voigtländer T, Nowak B, Genth S, Meyer J: Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046-1052.
11. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
12. Harker LA, Marcek UM, Kelly AB, Chronos NRF, Sundell IB, Hanson SR, Herbert JM: Enhancement of clopidogrel antithrombotic effects by aspirin for stent and vascular graft thrombosis in non-human primates (abstract). Thromb Haemost 1997;(suppl):565.
13. Altman R, Carreras L, Diaz R, Figueroa E, Paolasso E, Parodi JC, Cade JF, Donnan G, Eadie MJ, Gavaghan TP, O'Sullivan EF, Parkin D, Renny JTG, Silagy C, Vinazzer H, Zekert F, Adriaensen H, Bertrand Hardy JM, Bran M, et al: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308: 81-106.
14. Burns M, Becker RC, Every NR, Maynard C, Frederick P, Gore JM, Lambrew C: Current inhospital management of patients with non-ST segment elevation myocardial infarction: The National Registry of Myocardial Infarction Perspective (abstract). J Am Coll Cardiol 1998; (suppl):73.
15. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325:1137-1141.
16. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336: 973-979.
17. Balsano F, Violi F, Cimminiello C: Ticlopidine in unstable angina. Circulation 1990;82:2282-2283.
18. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-1220.
19. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501-507.
20. Savic M, Goy JJ, Shapira M, Kappenberger L: Antiaggregatory efficacy and tolerance of clopidogrel in percutaneous transluminal balloon angioplasty. A pilot study (abstract). Eur Heart 1995;16(suppl):417.
21. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
22. Schöming A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996;334:1084-1089.
23. Leon MB, Baim DS, Gordon P, Giambartolomei A, Williams DO, Diver DD, Senerchia C, Fitzpatrick M, Popma JJ, Kuntz RE: Clinical and angiographic results from the STent Anticoagulation Regimen Study (STARS) (abstract). Circulation 1996;94(suppl I):I-685.
24. Bertrand M, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L: Full anticoagulation versus ticlopidine plus aspirin after stent implantation: A randomized multicenter European study: The FANTASTIC trial (abstract). Circulation 1996;94:(suppl I):I-685.
25. Faulds D, Sorkin EM: Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994;48:583-598.
26. The EPIC Investigators: Use of a monoclonal antibody direct against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
27. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, et al: Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994;343:881-886.
28. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM: Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group: Evaluation of platelet IIb/IIIa inhbition for prevention of ischemic complication. JAMA 1997; 278:479-484.
29. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
30. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
31. The IMPACT Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II). Lancet 1997;349:1422-1428.
32. The RESTORE Investigators (Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis): Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplast. Circulation 1997;96:1445-1453.
33. Ferguson JJ: Meeting highlights. XIXth Congress of the European Society of Cardiology. Circulation 1997;96:3818-3821.
34. 33a The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
35. The PRISM Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-1505.
36. 34a The PRISM-PLUS Study Investigators: Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
37. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE: Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
38. 3) (abstract). J Am Coll Cardiol 1998;31(suppl A):55.
39. Antman EM, Giugliano RP, McCabe CH, Gibson M, Adgey AJJ, Ghali M, Coussement P, Anderson KM, Scherer J, Van de Werf F: Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of the TIMI 14 Trial (abstract). J Am Coll Cardiol 1998;31(suppl A):191.
40. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC: Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans. Circulation 1997;95:1755-1759.
41. Badimon JJ, Meyer B, Feigen LP, Baron DA, Chesebro JH, Fuster V, Badimon L: Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/ IIIa antagonist. Eur J Clin Invest 1997;27:568-574.
42. Cannon CP, Mc Cabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E: Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998;97:340-349.
43. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, de Franco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ: First chronic platelet glycoprotein IIb/IIIa integrin blockade: A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76-81.
44. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J: Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation 1997; 96:1130-1138.
45. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ: Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: Administration for complex coronary intervention. Circulation 1996;94:906-910.
46. Coller BS, Lang D, Scudder LE: Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997;95:860-867.
47. Vorchheimer DA, Fuster V: Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety. Circulation 1998; 97:312-314.